New Jersey, USA-headquartered Interlink Biotechnologies, a drug discovery firm focused on natural products, says that it will liquidate the assets of the company after what it described as "difficulties encountered in securing a suitable merger partner."
The company had been looking to join forces with another firm in a bid to continue to finance the continued expansion of its technology platform. Interlink said that the assets associated with its "substantial" capabilities included a screening ready library of pre-qualified, pre-fractionated natural product extracts, and that it plans to cease operations by end-August. For further information, visit: www.interlinkbiotech.com
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze